What is the recommended treatment for iron deficiency anemia with low ferritin?

Treatment of Iron Deficiency Anemia with Low Ferritin

Start with oral iron supplementation (ferrous sulfate 325 mg daily or on alternate days) as first-line therapy for most patients with iron deficiency anemia and low ferritin, but move directly to intravenous iron in specific clinical scenarios including inflammatory bowel disease with active inflammation, chronic kidney disease, heart failure, malabsorption disorders, intolerance to oral iron, ongoing blood loss, or during the second/third trimester of pregnancy 1, 2, 3.

Diagnostic Confirmation

Before initiating treatment, confirm iron deficiency using:

• Ferritin <30 μg/L in healthy individuals without inflammation 4, 3
• Ferritin <45 μg/L provides optimal sensitivity/specificity balance 1, 4
• Ferritin <100 μg/L with transferrin saturation <20% in patients with inflammatory conditions 4, 2, 3

The 2024 AGA guideline emphasizes that ferritin >45 μg/L but <100 μg/L may still indicate iron deficiency in inflammatory states, requiring confirmatory testing with transferrin saturation 1.

Treatment Algorithm

First-Line: Oral Iron Therapy

For patients without the contraindications listed below:

• Ferrous sulfate 325 mg daily (contains ~65 mg elemental iron) 2, 3
• Alternate-day dosing improves absorption and reduces gastrointestinal side effects 3
• Elemental iron dose: 3-6 mg/kg/day for optimal response 5
• Reassess in 2-4 weeks for hemoglobin response 3

Common pitfall: Approximately 50% of patients have poor adherence due to nausea, abdominal pain, and constipation 1, 3. If intolerance occurs, switch to alternate-day dosing or proceed to intravenous iron.

Direct to Intravenous Iron (Skip Oral)

The 2024 AGA guideline provides specific scenarios where IV iron should be used initially 1:

Gastrointestinal conditions:

• Inflammatory bowel disease with active inflammation - compromised absorption makes oral iron ineffective 1
• Celiac disease - if oral iron fails to improve stores despite gluten-free diet adherence 1
• Post-bariatric surgery - impaired absorption 2
• Atrophic gastritis or H. pylori infection - reduced iron absorption 1, 6

Chronic inflammatory conditions:

• Heart failure with ejection fraction <50% - IV iron improves symptoms, quality of life, functional capacity, and reduces hospitalization risk 2, 7
• Chronic kidney disease - functional iron deficiency common 2, 6
• Cancer patients - ongoing inflammation and blood loss 2

Other indications:

• Ongoing blood loss (portal hypertensive gastropathy, gastric antral vascular ectasia) unresponsive to oral iron 1
• Pregnancy (second/third trimester) - increased demand and urgency 2, 3
• Oral iron intolerance or failure - documented lack of response after 2-4 weeks 2, 3

Monitoring Response

• Recheck hemoglobin in 2-4 weeks for oral iron 3
• Repeat ferritin in 8-10 weeks to assess iron store repletion 8
• Target ferritin >30 μg/L for adults, >15-20 μg/L for children depending on age 8

Concurrent Management

Always identify and treat the underlying cause 1, 2:

• Evaluate menstrual blood loss in premenopausal women
• Perform bidirectional endoscopy in men and postmenopausal women 3
• Test for H. pylori and celiac disease (common causes) 1, 3
• Consider endoscopic treatment for angioectasias or vascular ectasia with thermal ablation or hemostatic clips 1
• Portal hypertension: add nonselective β-blockers if no other bleeding source identified 1

Key Caveats

Intravenous iron risks include hypersensitivity reactions (<1% with newer formulations), hypophosphatemia/osteomalacia, iron overload, and vascular leakage 6, 3. However, these risks are outweighed by benefits in the specific populations listed above.

Do not continue long-term iron supplementation once ferritin normalizes (>30-45 μg/L), as this provides no benefit and may be harmful 8. For patients with recurrent deficiency, use intermittent oral supplementation and monitor ferritin every 6-12 months 8.

The evidence strongly supports this tiered approach, with the 2024 AGA guideline 1 providing the most current and specific guidance for when to bypass oral therapy entirely.